Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Apr 26;8:6612. doi: 10.1038/s41598-018-24961-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Cytotoxicity of fDT-bound C7-Fc antibody in breast cancer cells with different levels of CD239 expression. (a) Flow cytometric analysis of CD239 expression in MCF7 cells (left panels) and transfectants (right panels). Solid lines show C7-Fc (CD239, upper panel) and Herceptin (HER2, lower panel); grey fill indicates Fc recombinant protein and control antibody. CD239 was highly expressed on transfectants. (b) Cytotoxicity of fDT-bound C7-Fc in parent cells (MCF7) and transfectants (CD239(Lu)MCF7). Cell proliferation was measured as described above. fDT-bound C7-Fc effectively killed CD239-overexpressing cells.